[Federal Register Volume 78, Number 247 (Tuesday, December 24, 2013)]
[Pages 77687-77688]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2013-30578]



Food and Drug Administration

[Docket No. FDA-2013-N-0001]

Science Advisory Board to the National Center for Toxicological 
Research; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.


    This notice announces a forthcoming meeting of a public advisory 
committee of the Food and Drug Administration (FDA). At least one 
portion of the meeting will be closed to the public.
    Name of Committee: Science Advisory Board (SAB) to the National 
Center for Toxicological Research (NCTR).
    General Function of the Committee: To provide advice and 
recommendations to the Agency on FDA's regulatory issues.
    Date and Time: The meeting will be held on January 29, 2014, from 
8:45 a.m. to 5:30 p.m. and on January 30, 2014, from 8 a.m. to 2 p.m.
    Location: NCTR SAB Conference Room B-12, 3900 NCTR Rd., Jefferson, 
AR 72079.
    Contact Person: Margaret Miller, Food and Drug Administration, 
10903 New Hampshire Ave., Bldg. 32, rm. 2208, Silver Spring, MD 20993-
0002, 301-796-8890, or FDA Advisory Committee Information Line, 1-800-
741-8138 (301-443-0572 in the Washington, DC area), to find out further 
information regarding FDA advisory committee information. A notice in 
the Federal Register about last minute modifications that impact a 
previously announced advisory committee meeting cannot always be 
published quickly enough to provide timely notice. Therefore, you 
should always check the Agency's Web site at http://www.fda.gov/AdvisoryCommittees/default.htm and scroll down to the appropriate 
advisory committee meeting link, or call the advisory committee 
information line to learn about possible modifications before coming to 
the meeting.
    Agenda: On January 29, 2014, the NCTR Director will welcome the 
participants and provide a Center-wide update on scientific initiatives 
and accomplishments during the past year. The SAB will be presented 
with an overview of the Division of Microbiology Subcommittee and the 
Subcommittee Site Visit Report. Following the public session, the SAB 
will hear an update from each of NCTR's research Division's the Office 

[[Page 77688]]

Science Coordination, followed by a report from the National Toxicology 
Program of the National Institutes of Environmental Health Sciences on 
current and future collaboration.
    On January 30, 2014, the Arkansas Bioinformatics Consortium will 
present concepts and ideas on defining and meeting NCTR and FDA's 
scientific computing needs and discuss how it can partner with FDA to 
foster the development of collaborative efforts in this area. To 
facilitate the discussion representatives from each of the product 
centers will discuss their bioinformatic needs, how those needs are 
being addressed and areas of possible collaboration.
    Following an open discussion of all the information presented, the 
open session of the meeting will close so that SAB members can discuss 
personnel issues at NCTR.
    FDA intends to make background material available to the public no 
later than 2 business days before the meeting. If FDA is unable to post 
the background material on its Web site prior to the meeting, the 
background material will be made publicly available at the location of 
the advisory committee meeting, and the background material will be 
posted on FDA's Web site after the meeting. Background material is 
available at http://www.fda.gov/AdvisoryCommittees/Calendar/default.htm. Scroll down to the appropriate advisory committee meeting 
    Procedure: On January 29, 2014, from 8:45 a.m. to 5 p.m., the 
meeting is open to the public. Interested persons may present data, 
information, or views, orally or in writing, on issues pending before 
the committee. Written submissions may be made to the contact person on 
or before January 21, 2014. Oral presentations from the public will be 
scheduled between approximately 12 p.m. to 2 p.m. Those individuals 
interested in making formal oral presentations should notify the 
contact person and submit a brief statement of the general nature of 
the evidence or arguments they wish to present, the names and addresses 
of proposed participants, and an indication of the approximate time 
requested to make their presentation on or before January 13, 2014. 
Time allotted for each presentation may be limited. If the number of 
registrants requesting to speak is greater than can be reasonably 
accommodated during the scheduled open public hearing session, FDA may 
conduct a lottery to determine the speakers for the scheduled open 
public hearing session. The contact person will notify interested 
persons regarding their request to speak by January 14, 2014.
    Closed Committee Deliberations: On January 30, 2014, from 11 a.m. 
to 2 p.m., the meeting will be closed to permit discussion where 
disclosure would constitute a clearly unwarranted invasion of personal 
privacy (5 U.S.C. 552b(c)(6)). This portion of the meeting will be 
closed to permit discussion of information concerning individuals 
associated with the research programs at NCTR.
    Persons attending FDA's advisory committee meetings are advised 
that the Agency is not responsible for providing access to electrical 
    FDA welcomes the attendance of the public at its advisory committee 
meetings and will make every effort to accommodate persons with 
physical disabilities or special needs. If you require special 
accommodations due to a disability, please contact Margaret Miller at 
least 7 days in advance of the meeting.
    FDA is committed to the orderly conduct of its advisory committee 
meetings. Please visit our Web site at http://www.fda.gov/AdvisoryCommittees/AboutAdvisoryCommittees/ucm111462.htm for procedures 
on public conduct during advisory committee meetings.
    Notice of this meeting is given under the Federal Advisory 
Committee Act (5 U.S.C. app. 2).

    Dated: December 17, 2013.
Jill Hartzler Warner,
Acting Associate Commissioner for Special Medical Programs.
[FR Doc. 2013-30578 Filed 12-23-13; 8:45 am]